公开(公告)号：US20220400669A1

公开(公告)日：2022-12-22

申请号：US17771717

申请日：2020-10-26

Applicant: King Abdullah University of Science and Technology ,  University of Tokyo

Inventor： Salim Albabili ,  Tadao Asami

IPC: A01N31/04 ,  C07C49/217 ,  C07C49/248 ,  C07C49/255 ,  A01N31/14 ,  A01N31/16

Abstract: Disclosed herein are compounds and methods for promoting plant growth. Formulations containing one or more disclosed compounds or salts thereof, and one or more excipients are disclosed. The formulation adjuvant can be a solid carrier, a liquid carrier, or a surface-active agent. Methods for promoting plant growth typically includes applying one or more formulations to a plant, a plant part, or a growing site of plant. The plant can be a cereal, grain, or vegetable plant. The plant part can be seed or seedling of a plant. The growing site of plant can be soil before, during, or after the plant is planted or a growing medium. In some embodiments, the one or more compounds or salts thereof in the one or more formulations are in an effective amount to decrease biosynthesis and release of strigolactone plant hormones from the plant.

公开(公告)号：US20220289657A1

公开(公告)日：2022-09-15

申请号：US17637565

申请日：2020-08-21

Applicant: KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION, SEJONG CAMPUS ,  KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION

Inventor： Youngjoo BYUN ,  Hee Deung PARK ,  Sangjin NAM ,  Sang-Hyun SON ,  So Young HAM ,  Han Shin KIM

IPC: C07C49/255 ,  C07C49/248 ,  C07C49/235 ,  A61K31/12 ,  A61P31/04

Abstract: The present invention relates to a 4-gingerol derivative compound, or a racemate, isomer, or pharmaceutically acceptable salt thereof, the compound being capable of inhibiting biofilm formation and production of virulence factors. The 4-gingerol derivative compound according to the present invention has binding affinity to RhlR and corresponding RhlR antagonism activity that are significantly improved, and therefore can effectively inhibit biofilm formation and production of virulence factors. Furthermore, various bacterial infectious diseases caused by biofilms can be fundamentally prevented or treated by using a pharmaceutical composition comprising the 4-gingerol derivative compound, or a racemate, isomer, or pharmaceutically acceptable salt thereof as an active ingredient.

公开(公告)号：US20190023680A1

公开(公告)日：2019-01-24

申请号：US16024368

申请日：2018-06-29

Applicant: James William Leahy ,  Zachary Paul Shultz ,  Grant Alexander Lawrence

Inventor： James William Leahy ,  Zachary Paul Shultz ,  Grant Alexander Lawrence

IPC: C07D311/80 ,  C07C45/67 ,  C07C45/41 ,  C07C67/08 ,  C07C45/68 ,  C07C29/143 ,  C07C29/132 ,  C07C69/533 ,  C07C49/248

Abstract: Provided are synthesis processes and intermediates for preparing cannabinoids and analogs.

公开(公告)号：US09988405B2

公开(公告)日：2018-06-05

申请号：US15596096

申请日：2017-05-16

Applicant: Neopanora Bio-technology (Zhuhai) Ltd.

Inventor： Xianzhang Bu ,  Cuige Zhu ,  Xin Yue ,  Yinglin Zuo ,  Yu Chen ,  Gesi Wen

IPC: C07C255/22 ,  C07C49/255 ,  C07C49/248 ,  C07C255/56 ,  C07C65/38 ,  C07C309/44 ,  C07D295/112 ,  C07F9/12 ,  C07F5/02 ,  C07C225/22

CPC classification number: C07F9/12 ,  C07C45/45 ,  C07C45/63 ,  C07C49/248 ,  C07C49/255 ,  C07C49/835 ,  C07C49/84 ,  C07C51/347 ,  C07C51/373 ,  C07C65/38 ,  C07C221/00 ,  C07C225/22 ,  C07C253/30 ,  C07C255/56 ,  C07C303/22 ,  C07C309/44 ,  C07D207/08 ,  C07D295/112 ,  C07D295/12 ,  C07F5/025 ,  C07C49/813

Abstract: Disclosed are an o-phenyl chalcone compounds and preparation methods and uses thereof. The o-phenyl chalcone compounds are capable of inhibiting the aggregation of microtubules in tumor cells and influencing the mitosis of the cells, and has a high antitumor activity. The compounds also have inhibitory activity against proliferation on various tumor cells, such as a human ovary cancer cell A2780, a human colon cancer cell HCT8, a human breast cancer cell MCF7, a human lung cancer cell A549, a human colon cancer cell SW480, a human nasopharyngeal carcinoma cell CNE2, a human liver cancer cell HepG2 and the like at nanomole concentrations.

公开(公告)号：US09074238B2

公开(公告)日：2015-07-07

申请号：US13467036

申请日：2012-05-08

Applicant: Chaur-Jong Hu ,  Po-Ting Chen ,  Rita P.-Y. Chen ,  Steven Sheng-Shih Wang

Inventor： Chaur-Jong Hu ,  Po-Ting Chen ,  Rita P.-Y. Chen ,  Steven Sheng-Shih Wang

IPC: A61K31/235 ,  C12Q1/37 ,  C07C49/248 ,  C07C59/84 ,  C07C59/90 ,  C07K7/06 ,  C07C49/255 ,  C07C49/235 ,  C07C225/22 ,  C12Q1/02 ,  G01N33/50 ,  C07C49/223 ,  C07K14/47

CPC classification number: C12Q1/37 ,  A61K31/235 ,  C07C49/223 ,  C07C49/235 ,  C07C49/248 ,  C07C49/255 ,  C07C59/90 ,  C07C225/22 ,  C07K7/06 ,  C07K14/4711 ,  C12Q1/025 ,  G01N33/5058 ,  G01N2333/4709 ,  G01N2500/00 ,  G01N2800/2821

Abstract: A method of enhancing neprilysin activity and/or degrading amyloid-β peptides and/or oligomers in a subject with Alzheimer's disease is disclosed. The method comprises administering to the subject a compound selected from the group consisting of in a therapeutically effective amount to enhance the neprilysin activity and/or degrade the amyloid-β peptides and oligomers in the subject. Methods of improving symptoms and/or retarding progression of Alzheimer's disease and prophylactic treatment and/or treatment of Alzheimer's disease are also disclosed.

Abstract translation: 增强血清蛋白酶活性和/或降解淀粉样蛋白的方法 公开了具有阿尔茨海默病的受试者中的肽和/或寡聚体。 该方法包括向受试者施用选自治疗有效量的化合物，以增强去血清活性和/或降解淀粉样蛋白; 肽和寡聚体。 还公开了改善阿尔茨海默病症状和/或延缓进展和预防性治疗和/或治疗阿尔茨海默病的方法。

公开(公告)号：US20150087705A1

公开(公告)日：2015-03-26

申请号：US14492294

申请日：2014-09-22

Applicant: Georgia Regents Research Institute, Inc.

Inventor： Cargill H. Alleyne, JR. ,  Krishnan M. Dhandapani ,  Ken Wen ,  MingLiang Ma ,  WenJing Hu

IPC: C07C49/248 ,  C07C59/90 ,  C07C69/738 ,  C07C49/235 ,  C07C49/255

CPC classification number: C07C49/248 ,  C07C49/235 ,  C07C49/255 ,  C07C59/90 ,  C07C69/738

Abstract: Disclosed herein are compounds, compositions and methods for preventing and treating diseases such as intracerebral hemorrhage, cancer, or conditions associated with damaged cells, activated lymphocytes, or microbial products. The disclosed compounds are curcumin analogs. The curcumin analogs possess anti-inflammatory and antioxidant properties, which in part, reduce AP-1 and NF-κB activity.

Abstract translation: 本文公开了用于预防和治疗诸如脑内出血，癌症或与损伤的细胞，活化的淋巴细胞或微生物产物相关的病症的疾病的化合物，组合物和方法。 所公开的化合物是姜黄素类似物。 姜黄素类似物具有抗炎和抗氧化性能，其部分地降低AP-1和NF-κB活性。

公开(公告)号：US20150031867A1

公开(公告)日：2015-01-29

申请号：US14344574

申请日：2012-09-05

Applicant: SNU R&DB FOUNDATION

Inventor： Seong Keun Kim ,  Seung Yang ,  Seon JIn Hwang ,  Jung Eun Lee ,  Jong Woo Lee ,  Jun Hee Kang ,  Eun Hak Lim

IPC: C07C49/248 ,  C08G63/12 ,  C07C49/255 ,  C07H15/207 ,  C09K11/06

CPC classification number: C09K11/06 ,  A61K49/0021 ,  A61K49/0052 ,  A61K49/0054 ,  C07C49/248 ,  C07C49/255 ,  C07H15/203 ,  C09K2211/1011

Abstract: The present invention provides a water-soluble fluorescent compound of resveratrone 6-O-β-glucoside [(E)-4-(8-hydroxy-6-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)naphthalen-2-yl)but-3-en-2-one] and its derivatives of Formula 1 which have at least one water-soluble substituent, and a method for preparing the same by a photochemical reaction of resveratrol 3-O-β-glucoside and its derivatives of having Formula 3 which are not fluorescent. Said new water-soluble fluorescent compounds has single-photon absorptive characteristics and/or two-photon absorptive characteristics as well as no or little toxicity, and can be usefully utilized in fields that requires water-soluble fluorescent characteristics (diagnosis, fluorescent probe, in vivo imaging, display, etc.).

Abstract translation: 本发明提供了白藜芦醇6-O-葡萄糖苷[（E）-4-（8-羟基-6 - （（（2S，3R，4S，5S，6R）-3）的水溶性荧光化合物， 4,5-三羟基-6-（羟甲基）四氢-2H-吡喃-2-基）氧基）萘-2-基）丁-3-烯-2-酮]及其衍生物，其具有至少一个 水溶性取代基，以及通过白藜芦醇3-O-和葡糖苷及其不具有荧光的式3的衍生物的光化学反应制备该水溶性取代基的方法。 所述新型水溶性荧光化合物具有单光子吸收特性和/或双光子吸收特性，无毒性或小毒性，可用于需要水溶性荧光特性的领域（诊断，荧光探针， 体内成像，显示等）。

公开(公告)号：US08895554B2

公开(公告)日：2014-11-25

申请号：US14042891

申请日：2013-10-01

Applicant: Proteotech Inc

Inventor： Alan D. Snow ,  Beth Nguyen ,  Gerardo Castillo ,  Virginia Sanders ,  Thomas Lake

IPC: A01N43/58 ,  A61K31/50 ,  A61K31/497 ,  A01N43/40 ,  A61K31/435 ,  C07D317/54 ,  C07D263/38 ,  C07D231/06 ,  C07D317/66 ,  C07D295/192 ,  C07D317/58 ,  C07D487/08 ,  C07D265/38 ,  C07D207/16 ,  C07D407/14 ,  C07D451/06 ,  C07C69/017 ,  C07C235/56 ,  C07D413/14 ,  C07C45/64 ,  C07C237/22 ,  C07D405/14 ,  C07C39/17 ,  C07D317/68 ,  C07D491/08 ,  C07D317/50 ,  C07C39/15 ,  C07C49/248 ,  C07C235/34 ,  C07C231/02 ,  C07D471/04 ,  C07D211/74 ,  C07C39/16 ,  C07C49/835 ,  C07C275/34 ,  C07C49/83 ,  C07C235/48 ,  C07D213/69 ,  C07D409/14 ,  C07C235/54 ,  C07D333/16 ,  C07D241/08 ,  C07C215/50 ,  C07D317/60 ,  C07D221/18 ,  C07D311/60 ,  C07C235/38 ,  C07D295/096 ,  C07C45/62 ,  C07D213/85 ,  C07D213/30 ,  C07D221/08

CPC classification number: C07C49/248 ,  A61K31/047 ,  C07C39/15 ,  C07C39/16 ,  C07C39/17 ,  C07C45/62 ,  C07C45/64 ,  C07C49/83 ,  C07C49/835 ,  C07C69/017 ,  C07C215/50 ,  C07C231/02 ,  C07C235/34 ,  C07C235/38 ,  C07C235/48 ,  C07C235/54 ,  C07C235/56 ,  C07C237/22 ,  C07C275/34 ,  C07D207/16 ,  C07D211/74 ,  C07D213/30 ,  C07D213/69 ,  C07D213/85 ,  C07D221/08 ,  C07D221/18 ,  C07D231/06 ,  C07D241/08 ,  C07D263/38 ,  C07D265/38 ,  C07D295/096 ,  C07D295/192 ,  C07D311/60 ,  C07D317/50 ,  C07D317/54 ,  C07D317/58 ,  C07D317/60 ,  C07D317/66 ,  C07D317/68 ,  C07D333/16 ,  C07D405/14 ,  C07D407/14 ,  C07D409/14 ,  C07D413/14 ,  C07D451/06 ,  C07D471/04 ,  C07D487/08 ,  C07D491/08

Abstract: Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of amyloid diseases, especially Aβ amyloidosis, such as observed in Alzheimer's disease, IAPP amyloidosis, such as observed in type 2 diabetes, and synucleinopathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment.

Abstract translation: 双 - 和三 - 二羟基芳基化合物及其亚甲二氧基类似物和药学上可接受的酯，它们的合成，含有它们的药物组合物及其在治疗淀粉样蛋白病，尤其是A＆ 诸如在阿尔茨海默病中观察到的淀粉样变性，诸如在2型糖尿病中观察到的IAPP淀粉样变性和诸如在帕金森病中观察到的突触核蛋白病，以及用于这种治疗的药物的制造。

公开(公告)号：US20130296422A1

公开(公告)日：2013-11-07

申请号：US13882647

申请日：2011-11-01

Applicant: Hiroyuki Saimoto ,  Kiyoshi Kita ,  Yoshisada Yabu ,  Masaichi Yamamoto

Inventor： Hiroyuki Saimoto ,  Kiyoshi Kita ,  Yoshisada Yabu ,  Masaichi Yamamoto

IPC: C07C255/53 ,  C07C47/27 ,  C07C49/248 ,  C07C59/90

CPC classification number: C07C255/53 ,  A61K31/047 ,  A61K45/06 ,  C07C47/27 ,  C07C47/56 ,  C07C47/575 ,  C07C49/248 ,  C07C49/258 ,  C07C49/835 ,  C07C49/84 ,  C07C59/74 ,  C07C59/90 ,  C07C69/738 ,  A61K2300/00

Abstract: Novel compounds below are useful for preventing or treating diseases caused by protozoans. At least one of a compound represented by Formula (I) (wherein, X represents a hydrogen atom or a halogen atom; R1 represents a hydrogen atom; R2 represents a hydrogen atom or a C1-7 alkyl group; R3 represents —CHO, —C(═O)R5, —COOR5 (wherein R5 represents a C1-7 alkyl group), —CH2OH or —COOH; and R4 represents a C1-16 alkyl group having one or more substituents on a terminal carbon atom and/or non-terminal carbon atom(s), a C2-16 alkenyl group having one or more substituents on a terminal carbon atom and/or non-terminal carbon atom(s), or a C2-16 alkynyl group having one or more substituents on a terminal carbon atom and/or non-terminal carbon atom(s)), an optical isomer thereof, and a pharmaceutically acceptable salt is used.

Abstract translation: 以下新型化合物可用于预防或治疗由原生动物引起的疾病。 由式（I）表示的化合物中的至少一种（其中，X表示氢原子或卤素原子; R1表示氢原子; R2表示氢原子或C1-7烷基; R3表示-CHO， - C（= O）R5，-COOR5（其中R5表示C1-7烷基），-CH2OH或-COOH; R4表示在末端碳原子上具有一个或多个取代基的C1-16烷基和/ - 末端碳原子，在末端碳原子和/或非末端碳原子上具有一个或多个取代基的C2-16烯基或在一个或多个取代基上具有一个或多个取代基的C 2-6-16炔基 末端碳原子和/或非末端碳原子），其旋光异构体和药学上可接受的盐。

公开(公告)号：US20130102498A1

公开(公告)日：2013-04-25

申请号：US13467036

申请日：2012-05-08

Applicant: Rita P.-Y. Chen ,  Steven Sheng-Shih Wang ,  Chaur-Jong Hu ,  Po-Ting CHEN

Inventor： Rita P.-Y. Chen ,  Steven Sheng-Shih Wang ,  Chaur-Jong Hu ,  Po-Ting CHEN

IPC: C12Q1/37 ,  C07C49/255 ,  C12Q1/02 ,  C07C49/248 ,  C07C49/235 ,  C07C225/22 ,  C07K7/06 ,  C07C59/90

CPC classification number: C12Q1/37 ,  A61K31/235 ,  C07C49/223 ,  C07C49/235 ,  C07C49/248 ,  C07C49/255 ,  C07C59/90 ,  C07C225/22 ,  C07K7/06 ,  C07K14/4711 ,  C12Q1/025 ,  G01N33/5058 ,  G01N2333/4709 ,  G01N2500/00 ,  G01N2800/2821

Abstract: Novel substrates for detection of activity of amyloid beta degrading enzyme, such as Neprilysin (NEP) and insulin degrading enzyme (IDE), associated with Alzheimer's disease, are provided. A quenched fluorogenic peptide substrate containing the first seven residues of the Aβpeptide plus a C-terminal Cys residue to detect neprilysin activity with a fluorophore attached to the C-terminal Cys and a quencher linked to the N-terminus of the peptide is disclosed. An assay system sensitive to endopeptidase activity of NEP and IDE, but insensitive to other Aβ-degrading enzymes is disclosed. Active compounds are identified by a cell-based assay system for high-throughput screening.

Abstract translation: 提供了用于检测与阿尔茨海默氏病有关的淀粉样蛋白β降解酶（例如尼泊替宁（NEP）和胰岛素降解酶（IDE））的活性的新型底物。 公开了含有Abetapeptide加上C末端Cys残基的前七个残基的淬灭的荧光肽底物，以检测与附着于C-末端Cys的荧光团和连接于该肽的N末端的猝灭剂的荧光素活性。 公开了对NEP和IDE的内肽酶活性敏感但对其它Aβ降解酶不敏感的测定系统。 通过用于高通量筛选的基于细胞的测定系统鉴定活性化合物。